Amyotrophic Lateral SclerosisPhase 1NCT07571174
A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
A Phase 1 study testing LY4256984 in people with Amyotrophic Lateral Sclerosis, run by Eli Lilly and Company at 11 sites in 5 countries.
Trial summary
The main purpose of this study is to assess the long-term safety and tolerability of LY4256984 in participants with Amyotrophic Lateral Sclerosis (ALS). This study is a long-term extension of study J6I-MC-OWAA (NCT07100119) and is part of the OLMP (NCT07571200) master protocol that will last approximately 96 weeks. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Amyotrophic Lateral Sclerosis
- What is being tested?
- LY4256984
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 32 participants
- Where
- 11 sitesin 5 countries
- Study dates
- 14 May 2026to Jun 2029
- Phase
- Phase 1
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Have completed the main treatment period/phase as well as any off-treatment period/phase of Study OWAA, the parent study for this ISA.
Who cannot join
- The participant has conditions that preclude a lumbar puncture (LP), such as:
- A history of clinically significant back pain, back pathology, and/or back injury (for example, degenerative disease, spinal deformity, or spinal surgery) that may predispose to complications or technical difficulty with LP.
- Allergy to local anesthetics, such as lidocaine or its derivatives.
- A local infection at the intended site of the LP.
- Less than 100 giga per liter [(<100 GI/L) is equivalent to 100,000 per cubic millimeter (100,000/mm³)] platelets or clinically significant coagulation abnormality or significant active bleeding, or
- Currently receiving treatment with an anticoagulant, antiplatelet agent, or other drug that affects coagulation or platelet function. Low dose (according to local medical guidelines) aspirin is permitted.
Trial locations and contacts
11 sites in 5 countries. Contact the study team or a site near you to ask about taking part.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or contact
Physicians interested in becoming principal investigators please contact contact
11 sites in 5 countries
Canada4 sites, 4 recruiting
- Not yet recruiting
Heritage Medical Research Clinic
Calgary, T2N 4Z6
Theodore Mobach
- Not yet recruiting
University Hospital - London Health Sciences Centre
London, N6A 5A5
Christen Shoesmith
- Recruiting
McGill University Health Centre
Montreal, H4A 3J1
Angela Genge
- Recruiting
Sunnybrook Research Institute
Toronto, M4N 3M5
Agessandro Abrahao
Germany3 sites, 3 recruiting
- Not yet recruiting
Universitätsklinikum Schleswig-Holstein
Lübeck, 23538
Julian Grosskreutz
- Not yet recruiting
Universitätsmedizin Rostock
Rostock, 18147
Andreas Hermann
- Not yet recruiting
Universitaetsklinikum Ulm
Ulm, 89081
Jochen Weishaupt
Spain2 sites, 2 recruiting
- Not yet recruiting
Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, 08907
MONICA POVEDANO PANADES
- Not yet recruiting
Hospital Universitari i Politecnic La Fe
Valencia, 46026
Juan Vazquez-Costa
Belgium1 site, 1 recruiting
- Not yet recruiting
UZ Leuven
Leuven, 3000
Philip Van Damme
Netherlands1 site, 1 recruiting
- Not yet recruiting
Universitair Medisch Centrum Utrecht
Utrecht, 3584 CX
Leonard H. Berg
About this study
Official title: A Study of Long-Term Safety, Tolerability, and Clinical Outcomes of Intrathecally Administered LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis: A Multicenter, Open-Label, Long-Term Extension of Study J6I-MC-OWAA
The main purpose of this study is to assess the long-term safety and tolerability of LY4256984 in participants with Amyotrophic Lateral Sclerosis (ALS). This study is a long-term extension of study J6I-MC-OWAA (NCT07100119) and is part of the OLMP (NCT07571200) master protocol that will last approximately 96 weeks.
- Conditions
- Amyotrophic Lateral Sclerosis
- Being tested
- LY4256984
- Medical subject headings
- Amyotrophic Lateral Sclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LY4256984Drug
Administered IT
| Study group | Role | What they receive |
|---|---|---|
| LY4256984 | Experimental | LY4256984 administered intrathecally (IT) Receives: Drug: LY4256984 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Measured: Baseline Up to Week 96
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 May 2026
- Study start14 May 2026
- Primary completionJun 2029 (estimated)
- Study completionJun 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Amyotrophic Lateral SclerosisStudies of the same condition, open and under way.
- More trials run by Eli Lilly and CompanyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 32 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Eli Lilly and Company
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Study director, Eli Lilly and Company
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07571174
- Sponsor's protocol ID
- 27887
- Other IDs
- L0U-MC-OL01, L0U-MC-OLMP, 2026-525574-19-00
- Status last verified
- Sep 2026
- First submitted
- 30 Apr 2026
- Last updated
- 22 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No